

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/131053 A1

(51) International Patent Classification:

C07K 16/46 (2006.01) A61K 31/551 (2006.01)
C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61K 47/68 (2017.01) A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2024/140953

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202311786110.0 22 December 2023 (22.12.2023) CN
202411857429.2 17 December 2024 (17.12.2024) CN

(71) Applicant: FORTVITA BIOLOGICS INC. [GB/GB];

Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavil-
ion, Hibiscus Way, 802 West Bay Road, Grand Cayman
KY1-1205 (KY).

(72) Inventors: HE, Kaijie; 168 Dongping Street, Suzhou In-

dustrial Park, Suzhou, Jiangsu 215123 (CN). ZHANG, Xi-
ao; 168 Dongping Street, Suzhou Industrial Park, Suzhou,
Jiangsu 215123 (CN). GUAN, Jian; 168 Dongping Street,
Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).
ZHOU, Shuaixiang; 168 Dongping Street, Suzhou Indus-
trial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: ZHONGZI LAW OFFICE; 7F, New Era Building,

26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: BISPECIFIC ANTIBODY-DRUG CONJUGATES TARGETING B7H3 AND EGFR AND THE USE THEREOF

(57) Abstract: Bispecific antibody-drug conjugates (ADCs) targeting B7H3 and EGFR and compositions containing the same are provided. Therapeutic and diagnostic uses of these antibodies and antibody fragments are also provided.

WO 2025/131053 A1